IMNR - The Immune Response Corporation should experience a relief of recent valuation depression this week.
The overhang of 600MM warrants * $0.02 per share is virtually gone. The warrants expire on 8/7/06, and with 3-day settlement warrant-holders are no longer able to sell and exercise their warrants. This should relieve enormous pressure from the stock. The financing has been absorbed. The next set of warrants do not become exercisable until October 16 through November 30.
Posts: 660 | From: california | Registered: Nov 2005
| IP: Logged |
IMNR.ob --STRONG BUY --WIN 1000% ----- Robert LeBoyer, who has more than 14 years of Wall Street experience. Prize Target 0.09 cents . Big announce soon . Start Phase 3 !!!! The Immune Response Corporation (OTCBB: IMNR) - Wednesday's shares closed down 3.11% to $0.0218. 5,245,489 shares were traded. The Immune Response Corporation announced on July 24th that IncreMental Advantage, an equity research firm, initiated coverage on the Company with an Accumulate rating, and a price target of $0.09 per share. The Immune Response Corporation's product pipeline has two clinical stage therapeutics in Phase II development, NeuroVax(TM) for multiple sclerosis (MS), and IR103 for HIV/AIDS. The report was issued by IncreMental's highly experienced biotechnology analyst, Robert LeBoyer, who has more than 14 years of Wall Street experience. IncreMental Advantage noted in the report that, "The current market capitalization is only $13.1 million. It is unusual to find such a company with two novel products in Phase II clinical trials." The Immune Response Corporation is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
IMNR.ob ---- NEW CEO --------Dr. Joseph O’Neill comes to The Immune Response Corporation ,After leading federal AIDS policy at the White House
After leading federal AIDS policy at the White House; the Office of the U.S. Secretary of Health and Human Services; and, the Office of the Global AIDS Coordinator at the U.S. Department of State. These positions, which were instrumental in formulating AIDS policy, have given him extensive experience and knowledge of the HIV/AIDS epidemic, its treatments, and the challenges for future treatments. Dr. O’Neill brings important relationships with drug development sponsors and researchers, as well as valuable experience